Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael N Dudley

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of the Pediatric Infectious Diseases Society|December 1, 2015
Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for EnterobacteriaceaeMichael N Dudley
Current Opinion in Biotechnology|November 28, 2008
Aerosol antibiotics: considerations in pharmacological and clinical evaluationMichael N Dudley, Jeff Loutit, David C Griffith
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic modelMatthew O'Brien, Thuy Quach, Deborah Gilbert, et al.
The Pediatric Infectious Disease Journal|November 14, 2003
Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulationJohn S Bradley, Michael N Dudley, George L Drusano
The Pediatric Infectious Disease Journal|September 7, 2013
Commentary: revised susceptibility breakpoints: fear, loathing and good scienceMichael N Dudley, Paul G Ambrose, Ronald N Jones
Antimicrobial Agents and Chemotherapy|November 7, 2018
Pharmacodynamics of Minocycline against <i>Acinetobacter baumannii</i> in a Rat Pneumonia ModelZiad Tarazi, Mojgan Sabet, Michael N Dudley, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2007
Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection modelDavid C Griffith, David Rodriguez, Erik Corcoran, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with MeropenemDavid C Griffith, Mojgan Sabet, Ziad Tarazi, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2021
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult SubjectsDavid C Griffith, Elizabeth E Morgan, Michael N Dudley, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of the Pediatric Infectious Diseases Society|December 1, 2015
Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for EnterobacteriaceaeMichael N Dudley
Current Opinion in Biotechnology|November 28, 2008
Aerosol antibiotics: considerations in pharmacological and clinical evaluationMichael N Dudley, Jeff Loutit, David C Griffith
Current Opinion in Pharmacology|November 13, 2017
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selectionMichael Trang, Michael N Dudley, Sujata M Bhavnani
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic modelMatthew O'Brien, Thuy Quach, Deborah Gilbert, et al.
The Pediatric Infectious Disease Journal|November 14, 2003
Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulationJohn S Bradley, Michael N Dudley, George L Drusano
The Pediatric Infectious Disease Journal|September 7, 2013
Commentary: revised susceptibility breakpoints: fear, loathing and good scienceMichael N Dudley, Paul G Ambrose, Ronald N Jones
Antimicrobial Agents and Chemotherapy|November 7, 2018
Pharmacodynamics of Minocycline against <i>Acinetobacter baumannii</i> in a Rat Pneumonia ModelZiad Tarazi, Mojgan Sabet, Michael N Dudley, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2007
Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection modelDavid C Griffith, David Rodriguez, Erik Corcoran, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with MeropenemDavid C Griffith, Mojgan Sabet, Ziad Tarazi, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2021
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult SubjectsDavid C Griffith, Elizabeth E Morgan, Michael N Dudley, et al.
Pageof 7